Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

ConclusionIn vitro, daratumumab is not toxic to mobilized CD34+  progenitor cells from myeloma patients.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research